LLY

874.01

+1.06%↑

UNH

527.35

-1.21%↓

JNJ

155.2

-0.46%↓

ABBV

192.85

+0.63%↑

NVO

81.68

-2.49%↓

LLY

874.01

+1.06%↑

UNH

527.35

-1.21%↓

JNJ

155.2

-0.46%↓

ABBV

192.85

+0.63%↑

NVO

81.68

-2.49%↓

LLY

874.01

+1.06%↑

UNH

527.35

-1.21%↓

JNJ

155.2

-0.46%↓

ABBV

192.85

+0.63%↑

NVO

81.68

-2.49%↓

LLY

874.01

+1.06%↑

UNH

527.35

-1.21%↓

JNJ

155.2

-0.46%↓

ABBV

192.85

+0.63%↑

NVO

81.68

-2.49%↓

LLY

874.01

+1.06%↑

UNH

527.35

-1.21%↓

JNJ

155.2

-0.46%↓

ABBV

192.85

+0.63%↑

NVO

81.68

-2.49%↓

Search

Biogen Inc

Cerrado

Sector Salud

133.29 -4.37

Resumen

Variación precio

24h

Actual

Mínimo

128.51

Máximo

139.28

Métricas clave

By Trading Economics

Ingresos

-195M

389M

Ventas

2.5B

P/B

Media del Sector

13.818

59.362

BPA

4.08

Margen de beneficio

15.729

EBITDA

-157M

762M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+41.1 upside

Dividendos

By Dow Jones

Próximas Ganancias

23 abr 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

21B

Apertura anterior

137.66

Cierre anterior

133.29

Noticias sobre sentimiento de mercado

By Acuity

65%

35%

350 / 393 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

Biogen Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

6 sept 2024, 11:00 UTC

Principales Noticias

Pandemic Darling Moderna Needs a Reality Check -- Heard on the Street -- WSJ

29 may 2024, 15:56 UTC

Ganancias
Adquisiciones, fusiones, absorciones

The Moderna Selloff Gains Steam. An Analyst Has a Few Theories Why. -- Barrons.com

Comparación entre iguales

Cambio de precio

Biogen Inc Esperado

Precio Objetivo

By TipRanks

41.1% repunte

Estimación a 12 meses

Media 201.12 USD  41.1%

Máximo 300 USD

Mínimo 138 USD

De acuerdo con 23 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Biogen Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

23 ratings

9

Comprar

14

Mantener

0

Vender

Puntuación técnica

By Trading Central

N/A / 142.34Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Weak Bearish Evidence

Sentimiento

By Acuity

350 / 393 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura bajista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.